Designer Drugs in Poland 2026 - Epidemic and Treatment

In 2024, Poland's Chief Sanitary Inspectorate recorded 2,719 poisonings caused by substitute substances and new psychoactive substances. That is 40% more than the year before and twice as many poisonings from designer drugs alone. The number of deaths linked to these substances reached 41, and the victims included children under 18. Designer drugs - technically new psychoactive substances (NPS) - have stopped being a marginal issue. Poland has become one of the leading markets for these compounds in Europe, and as 2026 begins the trend shows no sign of slowing. Treating addiction to them requires a different approach than classic narcotics.

At a glance

• In 2024, the GIS recorded 2,719 designer drug poisonings in Poland - a 40% year-on-year increase.
• 557 poisonings involved designer drugs alone; 92 cases involved children under 18.
• Of 41 deaths, 71% were caused by a single substance - NEP (N-ethylnorpentedrone) from the cathinone group.
• Treatment requires detox (5-10 days) followed by individual and group therapy, since no pharmacotherapy is targeted at NPS.

Designer drugs by the numbers - what the 2024 GIS report says

Data from the Chief Sanitary Inspectorate show a sharp rise in poisonings. In 2023, the monitoring system registered 1,698 cases. A year later the figure hit 2,719. Poisonings caused by designer drugs alone doubled - from fewer than 280 to 557.

The death toll reveals even more about the scale. Of 41 fatal cases, 71% were triggered by a single compound: NEP (N-ethylnorpentedrone) from the cathinone group. The Polish market is not uniform - certain highly toxic substances dominate.

The demographics surprise many. Men account for 67.5% of all cases, and the most affected age group is 30-39, where the largest year-on-year increase was recorded. Children are a minority, but 92 poisonings among people under 18 in a single year cannot be ignored.

The 2024 data are the latest full GIS report. Preliminary statistics for the first months of 2025 (through mid-May) already indicated nearly 1,200 poisonings - a pace close to the record year of 2024. As 2026 begins, designer drugs remain one of the most serious challenges facing Polish addiction psychiatry and emergency medicine, with new compounds - including N-ethylnorpentedrone (NEP), the subject of a special GIS warning issued in 2025 - reaching the market faster than regulators can respond.

Geography of poisonings

Regional distribution is strikingly uneven. The highest poisoning rates per 100,000 inhabitants were recorded in three voivodeships:

• Lubuskie - 6.48 cases per 100,000 inhabitants
• Małopolskie - 4.87 cases per 100,000
• Śląskie - 2.6 cases per 100,000

European data show Poland is not alone. The European Union Drugs Agency (EUDA, formerly EMCDDA) was monitoring more than 1,000 different NPS by the end of 2024, 47 of which had appeared for the first time that same year. Producers constantly modify molecules to evade legal controls - so the scale does not fall, it only changes shape.

Types of designer drugs - synthetic cannabinoids and cathinones

The informal term "designer drugs" covers dozens of chemical groups. In Poland, two dominate: synthetic cannabinoids and cathinones. Each works differently, triggers different symptoms, and requires a different medical approach.

Synthetic cannabinoids

Around 200 have been identified. They bind to CB1 and CB2 receptors in the brain - the same ones as THC - but tens to hundreds of times more tightly. They are not "synthetic marijuana" as dealers often claim. Their safety profile is entirely different.

Use of Spice- or K2-type mixtures causes:

• Hallucinations, paranoia, acute psychosis
• Hypertension, tachycardia, chest pain
• Seizures, loss of consciousness, coma
• Aggression and uncontrollable behaviour

For the once-popular MDMB-4en-PINACA, clinicians documented myocardial infarctions and strokes in people aged 20-30. Research indexed on PubMed shows that synthetic cannabinoids directly cause acute coronary syndromes in young users.

Cathinones

Cathinones are derivatives of cathinone - a natural compound found in the khat shrub (Catha edulis). They act as psychostimulants, but more potent than amphetamine or cocaine. Users feel a surge of energy and become hyperactive, talkative, euphoric and empathic. This combination of stimulation and empathogenic effect causes addiction to develop rapidly.

The earlier-mentioned NEP (N-ethylnorpentedrone) is a cathinone. Its extreme toxicity comes from a narrow safety window - the recreational and lethal doses differ only slightly. A 2024 analysis shows cathinones now account for most NPS-related deaths in Eastern Europe.

Why designer drugs are more dangerous than "classic" narcotics

Despite sharing the same addiction mechanism (how addiction works applies here just as it does with alcohol or opioids), designer drugs have several features that make them more hazardous.

First - unpredictable composition. The same mixture sold under the same brand may contain completely different active substances. Producers alter molecules faster than regulations can catch up. Someone who buys a "trusted" product today may get something entirely different next time.

Second - no toxicology tests. Standard drug tests fail to detect most NPS. Emergency medical teams often do not know what they are dealing with. Treatment of acute poisoning is therefore symptomatic - benzodiazepines for agitation, intravenous fluids, monitoring of vital signs.

Third - high potency. Some synthetic cannabinoids are hundreds of times stronger than THC. The gap between a pleasurable and a lethal dose can be smaller than a millimetre of measuring error.

Fourth - rapid addiction. The phases of drug addiction unfold much faster with designer drugs. Loss of control can follow the first use in weeks rather than years.

How designer drug addiction is treated

There is no registered pharmacotherapy in Poland targeted specifically at NPS. Naltrexone, acamprosate and disulfiram act on systems that designer drugs either do not use or use in modified ways. Treatment therefore rests on three pillars: detoxification, psychotherapy, and family support.

Detox

The first step is clearing the body and managing withdrawal. Withdrawal from designer drugs brings seizures, blood pressure swings, intense anxiety, insomnia, hallucinations and depressive states with suicidal thoughts. Severe cases require hospitalisation.

A typical course of medically supervised detox:

1. Days 1-3 - the hardest period, with symptoms at their peak. The patient receives tapering doses of benzodiazepines, intravenous fluids, B-group vitamins and antiemetics.
2. Days 4-7 - vital signs stabilise. Insight returns and the patient begins to feel emotions that were previously numbed by the substance.
3. Days 8-10 - preparation for further treatment. The therapeutic team performs a diagnostic assessment and discusses plans for inpatient or outpatient therapy.

Psychotherapy and support

After detox, the actual addiction treatment begins. For designer drugs, cognitive-behavioural addiction therapy and motivational interviewing work particularly well. At the same time, the patient attends group therapy, which helps rebuild social relationships - these tend to be more damaged among NPS users than among alcoholics, because the designer-drug market fosters closed, isolated circles.

Supplementary pharmacotherapy targets co-occurring symptoms: depression, anxiety, insomnia, psychosis. SSRIs, second-generation antipsychotics and mood stabilisers are selected individually based on the clinical picture.

The full recovery pathway is described in stages of recovery from drug addiction. For designer drugs, active treatment typically lasts 12-18 months, followed by years of abstinence maintenance.

When to seek help

There is no threshold below which designer drug use is "safe." Unlike alcohol, where risky and harmful drinking are recognised categories, any contact with NPS carries a risk of severe poisoning. Warning signs that warrant immediate specialist help:

• Episodes of unconsciousness, seizures or chest pain after use
• Growing anxiety, restlessness, insomnia between doses
• Isolation from family, changing social circle, deteriorating work or school performance
• Financial problems, valuables disappearing from home
• Psychotic symptoms (voices, delusions, paranoia) even after stopping use

Frequently asked questions

Do designer drugs cause addiction in the same way as classic narcotics?

Yes, the mechanism is identical. Designer drugs act on the brain's reward system, releasing dopamine and activating the same pathways as heroin, cocaine or amphetamine. The difference is that NPS do this more intensely and more quickly, so addiction develops over weeks rather than months. The psychological and social consequences match those of classic narcotics - loss of control, cravings, withdrawal from relationships and responsibilities.

How long does detox from designer drugs take?

Physical detox usually lasts 5-10 days, up to 14 days in severe cases. The first 72 hours are the hardest - withdrawal symptoms peak in this period. Detox should be medically supervised because complications (seizures, psychosis, suicidal ideation) may require immediate intervention. Once detox is complete, the patient moves into psychotherapy and further treatment.

Do drug tests detect designer drugs?

Standard rapid tests (the panels sold in pharmacies) do not detect most NPS. Producers deliberately alter chemical structures to slip past controls. Specialist laboratories can identify some substances, but the cost and analysis time are high. This is one reason designer drugs remain popular among people subject to testing (employees, drivers, individuals under supervision).

What to do when someone close has taken designer drugs and is losing consciousness?

Call emergency services immediately (112). While waiting for the ambulance: place the person in the recovery position (on their side), monitor breathing, do not give food or drink. If possible, secure the packaging or any remaining substance - this helps the medical team choose the right treatment. Do not induce vomiting. If breathing stops, begin cardiopulmonary resuscitation.

Can designer drug addiction be treated at home?

Self-directed detox is strongly discouraged and can be dangerous. Stopping NPS can trigger seizures, cardiac arrhythmias and acute psychotic states. Even after physical symptoms ease, the risk of relapse in the first months remains very high - professional therapy is essential. Outpatient treatment in milder cases and inpatient treatment in severe addiction are both realistic options, but neither can replace the support of a therapeutic team.